Literature DB >> 24681664

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

Nobuyuki Okamura1, Shozo Furumoto2, Michelle T Fodero-Tavoletti3, Rachel S Mulligan4, Ryuichi Harada5, Paul Yates4, Svetlana Pejoska4, Yukitsuka Kudo6, Colin L Masters7, Kazuhiko Yanai8, Christopher C Rowe4, Victor L Villemagne3.   

Abstract

Non-invasive imaging of tau pathology in the living brain would be useful for accurately diagnosing Alzheimer's disease, tracking disease progression, and evaluating the treatment efficacy of disease-specific therapeutics. In this study, we evaluated the clinical usefulness of a novel tau-imaging positron emission tomography tracer 18F-THK5105 in 16 human subjects including eight patients with Alzheimer's disease (three male and five females, 66-82 years) and eight healthy elderly controls (three male and five females, 63-76 years). All participants underwent neuropsychological examination and 3D magnetic resonance imaging, as well as both 18F-THK5105 and 11C-Pittsburgh compound B positron emission tomography scans. Standard uptake value ratios at 90-100 min and 40-70 min post-injection were calculated for 18F-THK5105 and 11C-Pittsburgh compound B, respectively, using the cerebellar cortex as the reference region. As a result, significantly higher 18F-THK5105 retention was observed in the temporal, parietal, posterior cingulate, frontal and mesial temporal cortices of patients with Alzheimer's disease compared with healthy control subjects. In patients with Alzheimer's disease, the inferior temporal cortex, which is an area known to contain high densities of neurofibrillary tangles in the Alzheimer's disease brain, showed prominent 18F-THK5105 retention. Compared with high frequency (100%) of 18F-THK5105 retention in the temporal cortex of patients with Alzheimer's disease, frontal 18F-THK5105 retention was less frequent (37.5%) and was only observed in cases with moderate-to-severe Alzheimer's disease. In contrast, 11C-Pittsburgh compound B retention was highest in the posterior cingulate cortex, followed by the ventrolateral prefrontal, anterior cingulate, and superior temporal cortices, and did not correlate with 18F-THK5105 retention in the neocortex. In healthy control subjects, 18F-THK5105 retention was ∼10% higher in the mesial temporal cortex than in the neocortex. Notably, unlike 11C-Pittsburgh compound B, 18F-THK5105 retention was significantly correlated with cognitive parameters, hippocampal and whole brain grey matter volumes, which was consistent with findings from previous post-mortem studies showing significant correlations of neurofibrillary tangle density with dementia severity or neuronal loss. From these results, 18F-THK5105 positron emission tomography is considered to be useful for the non-invasive assessment of tau pathology in the living brain. This technique would be applicable to the longitudinal evaluation of tau deposition and allow a better understanding of the pathophysiology of Alzheimer's disease.
© The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; Alzheimer’s disease pathology; PET; amyloid; positron emission tomography

Mesh:

Substances:

Year:  2014        PMID: 24681664     DOI: 10.1093/brain/awu064

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  98 in total

Review 1.  Multimodality Review of Amyloid-related Diseases of the Central Nervous System.

Authors:  Michelle M Miller-Thomas; Adam L Sipe; Tammie L S Benzinger; Jonathan McConathy; Sarah Connolly; Katherine E Schwetye
Journal:  Radiographics       Date:  2016 Jul-Aug       Impact factor: 5.333

Review 2.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

3.  Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.

Authors:  Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Madeleine Harris; Christine Ghadery; Jinhee Kim; Anthony E Lang; Alan Wilson; Sylvain Houle; Antonio P Strafella
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-22       Impact factor: 6.200

4.  The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.

Authors:  N Maritza Dowling; Sterling C Johnson; Carey E Gleason; William J Jagust
Journal:  Neuroimage       Date:  2014-10-29       Impact factor: 6.556

Review 5.  Imaging pathological tau in atypical parkinsonian disorders.

Authors:  Sarah Coakeley; Antonio P Strafella
Journal:  Curr Opin Neurol       Date:  2015-08       Impact factor: 5.710

Review 6.  Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions.

Authors:  Aaron J Carman; Rennie Ferguson; Robert Cantu; R Dawn Comstock; Penny A Dacks; Steven T DeKosky; Sam Gandy; James Gilbert; Chad Gilliland; Gerard Gioia; Christopher Giza; Michael Greicius; Brian Hainline; Ronald L Hayes; James Hendrix; Barry Jordan; James Kovach; Rachel F Lane; Rebekah Mannix; Thomas Murray; Tad Seifert; Diana W Shineman; Eric Warren; Elisabeth Wilde; Huntington Willard; Howard M Fillit
Journal:  Nat Rev Neurol       Date:  2015-03-17       Impact factor: 42.937

Review 7.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 8.  Tau PET imaging in Alzheimer's disease.

Authors:  Nobuyuki Okamura; Ryuichi Harada; Shozo Furumoto; Hiroyuki Arai; Kazuhiko Yanai; Yukitsuka Kudo
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

9.  Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.

Authors:  Dustin W Wooten; Nicolas J Guehl; Eline E Verwer; Timothy M Shoup; Daniel L Yokell; Nevena Zubcevik; Neil Vasdev; Ross D Zafonte; Keith A Johnson; Georges El Fakhri; Marc D Normandin
Journal:  J Nucl Med       Date:  2016-09-22       Impact factor: 10.057

10.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Authors:  Liang Wang; Tammie L Benzinger; Yi Su; Jon Christensen; Karl Friedrichsen; Patricia Aldea; Jonathan McConathy; Nigel J Cairns; Anne M Fagan; John C Morris; Beau M Ances
Journal:  JAMA Neurol       Date:  2016-09-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.